CL2A (TFA)

• Description :

  CL2A TFA is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A TFA is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker[1].

• UNSPSC :

  12352203

• Target :

  ADC Linker

• Type :

  ADC Related

• Related Pathways :

  Antibody-drug Conjugate/ADC Related

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/cl2a-tfa.html

• Purity :

  99.49

• Solubility :

  DMSO : 222.5 mg/mL (ultrasonic)

• Smiles :

  O=C(O)C(F)(F)F.O=C(NC1=CC=C(CO)C=C1)[C@H](CCCCN)NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN2N=NC(CNC(C3CCC(CN4C(C=CC4=O)=O)CC3)=O)=C2)=O)=O

• Molecular Formula :

  C52H80F3N9O18

• Molecular Weight :

  1176.24

• References & Citations :

  [1]Samantha Congreve, et al. Antibody drug conjugates (ADC) . Teknisk- naturvetenskaplig fakultet

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  ADC Related

• Clinical Information :

  No Development Reported